Clinical Edge Journal Scan

Diagnosing and managing depression before and after BC diagnosis may improve survival outcomes


 

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Recommended Reading

Patritumab deruxtecan shows promise for breast cancer patients
Breast Cancer ICYMI
Atezolizumab is associated with enhanced response in triple-negative breast cancer
Breast Cancer ICYMI
Genomic assay changes minds on HER2+ BC treatment
Breast Cancer ICYMI
Trastuzumab deruxtecan bests standard-of-care in trastuzumab emtansine-resistant HER2+ metastatic BC
Breast Cancer ICYMI
Slower decrease in mammographic breast density observed in women who developed breast cancer
Breast Cancer ICYMI
Antibiotic use after TNBC diagnosis associated with worse survival outcomes
Breast Cancer ICYMI
High-risk HR+/HER2− early BC: Higher pCR rate with neoadjuvant nab-paclitaxel vs dose-dense solvent-based paclitaxel
Breast Cancer ICYMI
Extending anastrozole treatment beyond 5 years may benefit postmenopausal HR+ BC patients
Breast Cancer ICYMI
ER+/HER2− BC: Real-world data show improvement in OS with chemotherapy plus ET
Breast Cancer ICYMI
Pathogenic variants in PALB2 and ATM genes associated with increased male BC risk
Breast Cancer ICYMI